DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: regadenoson

Summary for Generic Name: regadenoson

Tradenames:1
Patents:14
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers: see list1

Pharmacology for Ingredient: regadenoson

Clinical Trials for: regadenoson

Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation
Status: Recruiting Condition: Myocardial Blood Flow Reserve

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
Status: Active, not recruiting Condition: Coronary Artery Disease (CAD)

Regadenoson to Achieve Maximal Hyperemia for Fractional Flow Reserve in the Catheterization Lab
Status: Recruiting Condition: Coronary Artery Disease

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)
Status: Completed Condition: Coronary Artery Disease; Type 1 Diabetes Mellitus

Regadenoson and Adenosine
Status: Completed Condition: Coronary Artery Disease

A Phase II Trial of Regadenoson in Sickle Cell Anemia
Status: Recruiting Condition: Sickle Cell Anemia

ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Status: Completed Condition: Coronary Artery Disease

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Status: Completed Condition: Coronary Artery Disease

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson
Status: Completed Condition: Ischemic Heart Disease

Regadenoson Real Time Perfusion Imaging Trial-Optison
Status: Recruiting Condition: Coronary Artery Disease; Myocardial Perfusion Abnormalities

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161Apr 10, 2008RXYes8,133,879<disabled>Y
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161Apr 10, 2008RXYes8,106,183<disabled>Y
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161Apr 10, 2008RXYes8,470,801<disabled>METHOD OF MYOCARDIAL IMAGING
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161Apr 10, 2008RXYes8,536,150<disabled>METHOD OF MYOCARDIAL IMAGING
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc